Navigation Links
Major Manufacturer of Unapproved and Adulterated Drugs


warnings in their labeling.

According to the complaint filed with the court, PharmaFab did not comply with CGMP by not investigating manufacturing failures and not recording and justifying why it deviated from written manufacturing procedures. Further, the company lacked an effective quality control unit and failed to establish reliable expiration dates for products. Compliance with CGMP is necessary to ensure that drugs have the requisite safety, identity, strength, quality, and purity.

The consent decree requires the defendants to destroy certain illegal drugs, and bars them from distributing all drugs until they obtain required FDA approval and fully comply with CGMP. If they resume distributing drugs, the defendants are required to retain an auditor to conduct inspections of their facilities for a period of five years and to provide reports to FDA analyzing compliance with CGMP and labeling requirements. The decree also allows FDA to require recall or shutdown in the event of future violations and provides for damages of $5,000 per day and $1,000 per violation, up to a maximum of $5 million per year, if the defendants fail to comply with its terms.

“FDA will not hesitate to pursue enforcement action when necessary,” said Margaret O’K. Glavin, FDA's associate commissioner for regulatory affairs. “We will continue to protect public health by carefully monitoring the provisions of this injunction. FDA will also continue to investigate and take action against other marketers of unapproved drugs.”

In June 2006, FDA issued a guidance document entitled, “Marketed Unapproved Drugs—Compliance Policy Guide” (CPG). The CPG makes clear that firms may not market drugs that require approval without first establishing in applications that the products are safe and effective. One of the priorities in this CPG is enforcement actions against manufacturers that violate other provisions of the Federa
'"/>




Page: 1 2 3

Related medicine technology :

1. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
2. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
3. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
4. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
5. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
6. Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data
7. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
8. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
9. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
10. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
11. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Major Manufacturer Unapproved and Adulterated Drugs
(Date:12/16/2009)... Dec. 16 Verathon®, maker of ... announce that portable bladder volume ultrasound is ... guidelines for the Prevention of Catheter-Associated Urinary ... guidelines, introduced in early November 2009, replace ... 1981. The guidelines are located on ...
(Date:12/16/2009)... Dec. 16 According to Millennium Research ... market intelligence, health care reforms in China supported ... in 2009, and will continue to fuel growth ... Asia Pacific Markets for Interventional Cardiology Devices 2010 ... Chinese government will allow the Chinese drug-eluting stent ...
(Date:12/16/2009)... -- Greenway Medical Technologies, Inc. today announced that ... practice management and interoperability solution, Prime Suite® ... the annual 2009 Top 20 Best in ... report. ,, For practices having between six and ... Best in KLAS in ambulatory EMR for the ...
Breaking Medicine Technology:New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 2New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 4New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 5Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 2Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 4Micromet Announces Public Offering of Common Stock 13262 1Micromet Announces Public Offering of Common Stock 13262 2Micromet Announces Public Offering of Common Stock 13262 3Micromet Announces Public Offering of Common Stock 13262 4Osteotech Resumes Shipments of Bulgarian Tissue 13259 1Osteotech Resumes Shipments of Bulgarian Tissue 13259 2Osteotech Resumes Shipments of Bulgarian Tissue 13259 3PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5 2009 13256 1
... of non-animal alternative test methods , , ... announced that the ECVAM Scientific Advisory Committee (ESAC) endorsed the ... at its November meeting. ESAC concluded that the Modified ... of skin irritating and non-irritating test substances. , ...
... DCTH ) today announced the appointment of Pamela R. ... a proven corporate executive with extensive experience working with international and ... (LOGO: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ) , , ... served as CEO. Prior to starting Cobalt, she founded Xenogen ...
Other Medicine Technology:EpiDerm's Skin Irritation Test Fully Validated in European Union 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 3
(Date:12/16/2009)... CHICAGO, Dec. 16 Allscripts (Nasdaq: ... its financial results for the three and six ... market opens on Monday, January 11, 2010. Allscripts ... to discuss the company,s earnings and other information ... morning. ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, ...
(Date:12/16/2009)... HealthSciences Institute will sponsor a new learning ... organizations who serve individuals at risk of, ... health plan, medical home and other provider ... noncommercial webinars on topics, solutions and case ... care improvement. Each webinar will include a ...
(Date:12/16/2009)... Institute announce the first comprehensive analyses of cancer genomes. ... the DNA of cancer cells which are acquired during ... and a lung cancer, reveal for the first time ... cancers. , Lung cancer causes around one million deaths ... The number of mutations found suggest that a typical ...
(Date:12/16/2009)... Planet-Friendly Organics, Solar-Powered Manufacturing and Sustainable Packaging at an Affordable ... ... Angeles, CA (PRWEB) December 16, 2009 -- Actively healthy families ... all natural skin care for their children as Episencial ... featuring the beloved artwork of The Very Hungry Caterpillar from ...
(Date:12/16/2009)... leader of Digital Pen and Paper technology and the provider ... today announced that it is ranked among the Fastest Growing ... 2009. , ... (PRWEB) December 16, ... for the capture, digitalization and management of handwritten data. Kayentis ...
Breaking Medicine News(10 mins):Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 2Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 3Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 4Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 5Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2
... found that the Schering-Plough fungus-fighter drug - Noxafil, //which ... in protecting patients with crippled immune systems, according to ... of their study were published in the New England ... fungal infections, Noxafil, known generically as posaconazole, also seems ...
... Health Organization, Dr. Margaret Chan is very optimistic about dealing ... cites the case of measles to point out that with ... ,WHO reports released last week depict that deaths from measles ... by 75 percent in the past five years. ...
... proposals will fundamentally change the way that primary care ... to advance patient-centered// primary care were released today by ... report on The State of the Nation's Health Care. ... a collapse of primary care medicine, the ACP reported ...
... is ranked second in the list of ‘deadliest’ cancers, which ... to diagnose the disease in// the early stage. The Ontario ... program for colorectal cancer. This plan will adopt two crucial ... ,The envisaged five year screening program for men aged 50 ...
... the Department of Chemistry at the University of York have ... carbon// monoxide in treating disease. ,The Scientists have ... three-year study into the use of metal compounds for the ... ,Carbon monoxide is an anti-inflammatory, and they want to explore ...
... that point to yet another benefit of statins; improving survival ... for heart patients. They work by lowering the levels of ... arteries. ,The drugs have also been shown to ... heart disease from having a heart attack or stroke. ...
Other Medicine News:Health News:Comprehensive Reforms to Move Toward Patient-Centered Care 2Health News:Comprehensive Reforms to Move Toward Patient-Centered Care 3Health News:Benefits of Carbon Monoxide 2Health News:Statins Aid Survival in Lung Patients, Say Experts 2
... the durability of natural tissue ... of ingrowth and natural adaptation ... exceeds all applicable state and ... Tissue also reduces OR time ...
Meets the demanding requirements of most pelvic floor reconstructive procedures, and is highly resistant to suture pull-through, demonstrating long-term durability, and serves as a structural support...
... The FineTech-Brindley (also known as the ... which has been used by people with ... (or urinate) on demand. A secondary use ... bowel evacuation and promote penile erection.,The Bladder ...
... Nephrostomy Balloon is used to dilate the ... nephrostomy tract during a percutaneous procedure. The ... from the balloon to the catheter shaft ... close approximation of the dilating tract to ...
Medicine Products: